- Home
- PSF vs SERA Comparison
PSF vs SERA Comparison
Compare PSF & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- SERA
- Stock Information
- Founded
- PSF 2010
- SERA 2008
- Country
- PSF United States
- SERA United States
- Employees
- PSF N/A
- SERA N/A
- Industry
- PSF Investment Managers
- SERA Precision Instruments
- Sector
- PSF Finance
- SERA Health Care
- Exchange
- PSF Nasdaq
- SERA Nasdaq
- Market Cap
- PSF 256.1M
- SERA 258.3M
- IPO Year
- PSF N/A
- SERA 2021
- Fundamental
- Price
- PSF $21.26
- SERA $6.43
- Analyst Decision
- PSF
- SERA
- Analyst Count
- PSF 0
- SERA 0
- Target Price
- PSF N/A
- SERA N/A
- AVG Volume (30 Days)
- PSF 25.0K
- SERA 135.8K
- Earning Date
- PSF 01-01-0001
- SERA 11-06-2024
- Dividend Yield
- PSF 7.69%
- SERA N/A
- EPS Growth
- PSF N/A
- SERA N/A
- EPS
- PSF N/A
- SERA N/A
- Revenue
- PSF N/A
- SERA $107,000.00
- Revenue This Year
- PSF N/A
- SERA N/A
- Revenue Next Year
- PSF N/A
- SERA $2,020.00
- P/E Ratio
- PSF N/A
- SERA N/A
- Revenue Growth
- PSF N/A
- SERA N/A
- 52 Week Low
- PSF $16.00
- SERA $1.56
- 52 Week High
- PSF $20.19
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- PSF 62.78
- SERA 36.51
- Support Level
- PSF $21.11
- SERA $6.87
- Resistance Level
- PSF $21.39
- SERA $7.27
- Average True Range (ATR)
- PSF 0.17
- SERA 0.50
- MACD
- PSF -0.03
- SERA -0.13
- Stochastic Oscillator
- PSF 52.08
- SERA 7.85
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.